

Special Issue

Perioperative and Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Message from the Guest Editors

Perioperative and neoadjuvant immunotherapy regimens have recently been adopted as preferred treatment approach for patients with resectable stage II-III non-small-cell lung cancer. The addition of checkpoint inhibitors to neoadjuvant chemotherapy plus or minus adjuvant immunotherapy has shown to improve pathological response rates, event-free survival and overall survival compared to neoadjuvant chemotherapy alone in multiple phase 3 trials. The advantages of the administration of effective systemic treatment in the neoadjuvant setting include early treatment of micrometastatic disease, high patient compliance and the opportunity for pathological response evaluation to potentially impact further postoperative treatment. In this Special Issue, we would like to review current trial data on this novel approach of perioperative and neoadjuvant immunotherapy and also discuss challenges and questions.

Guest Editors

Dr. Martin Frueh

1. Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland

2. Faculty of Medicine, University of Bern, Murtenstrasse 11, 3008 Bern, Switzerland

Dr. Kira-Lee Koster

Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland

Deadline for manuscript submissions

closed (31 May 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/220135

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)